Tail-Engineered Phage P2 Enables Delivery of Antimicrobials into Multiple Gut Pathogens

ACS Synth Biol. 2023 Feb 17;12(2):596-607. doi: 10.1021/acssynbio.2c00615. Epub 2023 Feb 2.

Abstract

Bacteriophages can be reprogrammed to deliver antimicrobials for therapeutic and biocontrol purposes and are a promising alternative treatment to antimicrobial-resistant bacteria. Here, we developed a bacteriophage P4 cosmid system for the delivery of a Cas9 antimicrobial into clinically relevant human gut pathogens Shigella flexneri and Escherichia coli O157:H7. Our P4 cosmid design produces a high titer of cosmid-transducing units without contamination by a helper phage. Further, we demonstrate that genetic engineering of the phage tail fiber improves the transduction efficiency of cosmid DNA in S. flexneri M90T as well as allows recognition of a nonnative host, E. coli O157:H7. We show that the transducing units with the chimeric tails enhanced the overall Cas9-mediated killing of both pathogens. This study demonstrates the potential of our P4 cas9 cosmid system as a DNA sequence-specific antimicrobial against clinically relevant gut pathogenic bacteria.

Keywords: Cas9 antimicrobial; Escherichia coli O157:H7; Shigella flexneri; bacteriophage P2/P4; phage-based delivery vector; tail fiber engineering.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteriophage P2*
  • Bacteriophages* / genetics
  • Escherichia coli O157* / genetics
  • Humans